Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

129.49 -2.47 (-1.87%)
Streaming Delayed Price Updated: 2:47 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Beigene Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
From BeiGene, Ltd.
Via Business Wire
BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in 3/13 Morning Trading
Via Investor Brand Network
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
From BeiGene
Via Business Wire
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene, Ltd.
Via Business Wire
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
From BeiGene, Ltd.
Via Business Wire
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
From BeiGene, Ltd.
Via Business Wire
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
From BeiGene, Ltd.
Via Business Wire
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
From BeiGene, Ltd.
Via Business Wire
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the Jefferies London Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
From BeiGene
Via Business Wire
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
From BeiGene, Ltd.
Via Business Wire
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From BeiGene
Via Business Wire
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
From BeiGene, Ltd.
Via Business Wire
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
Exposures Death
Bragar Eagel & Squire, P.C. Is Investigating Viasat and BeiGene and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
From BeiGene
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.